Skip to main content
. 2021 Sep 2;39(33):3671–3681. doi: 10.1200/JCO.21.00334

FIG A1.

FIG A1.

Percentage change in target tumor diameter from baseline over time for the RES population: (A) Nivolumab and (B) GEM or PLD; and for the responders: (C) Nivolumab and (D) GEM or PLD. GEM, gemcitabine; PLD, pegylated liposomal doxorubicin; RES, response-evaluable set.